Market Overview

Myriad Says Utah Medicare Will Add Prostate Test to Next Draft Non-Covered Service LCD


Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that Noridian, the Medicare Administrator for Utah, has notified Myriad of its intent to add the Company's prostate prognostic test, Prolaris®, to its next draft Non-Covered Service LCD (local coverage determination). Noridian will solicit public and provider comment on the Prolaris test before making a final decision.

Posted-In: News FDA


Related Articles (MYGN)

View Comments and Join the Discussion!